NON SMALL CELL LUNG CANCER

This study tested whether a subcutaneous (under-the-skin) injection of the immunotherapy drug atezolizumab works as well as the standard intravenous (IV) infusion in people with advanced non-small cell lung cancer who had already tried platinum-based chemotherapy. The trial enrol…

This phase 2 trial tested a new drug called BA3011, alone or with an immunotherapy, in 85 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study is now complet…

This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy combines an immune booster with cancer-specific pep…

This phase 3 trial tested the drug pembrolizumab (Keytruda) against a placebo in 1,177 people with early-stage non-small cell lung cancer who had already had surgery. The goal was to see if pembrolizumab could delay the cancer from coming back. Participants received either the dr…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This phase II trial tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy (paclitaxel) in 46 people with untreated metastatic non-small cell lung cancer. The goal was to see if the mix could slow cancer growth and be safe. Results may point …

This completed study looked at how safe sotorasib is for Chinese patients with a certain type of advanced lung cancer (KRAS G12C-mutated NSCLC). 102 patients who had already tried other treatments took sotorasib pills daily. Researchers tracked side effects and how long patients …

This early-phase trial tested a new drug called GDC-1971 in combination with either osimertinib (for non-small cell lung cancer) or cetuximab (for colorectal cancer). The study involved 10 participants with advanced or metastatic disease that had progressed after prior treatments…

This phase 3 trial tested whether adding plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. 559 participants who had already tried one or two prior treatments were randomly assigned to receive either docetaxel plus p…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This early-phase trial tested whether injecting the chemotherapy drug cisplatin directly into lung tumors (during a bronchoscopy) is safe for people with early-stage, resectable non-small cell lung cancer. Only 6 participants were enrolled, and the main goal was to find the highe…

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This study tested a new way to deliver a single, high-dose radiation treatment (SBRT) for small lung tumors. Normally, this process takes two to three weeks and multiple hospital visits. The new 'ONE STOP' approach aims to do everything—from planning to treatment—in just a few ho…

This phase 3 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The study compared the combin…

This early-phase study tested a personalized therapy where immune cells are taken from a patient's own tumor, grown in large numbers in a lab, and then infused back into the patient. The goal was to see if this treatment is safe and can shrink advanced solid tumors like melanoma,…

This early-phase study tested a combination of two drugs, bexarotene and Iressa, in 6 people with advanced non-small cell lung cancer who had already tried standard treatments. The goal was to see if the combination was safe and could help control the disease. The study looked at…

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy could help people with advanced central non-small cell lung cancer. The trial included 33 adults whose cancer could not be surgically removed. The goal was to see if the tr…

This study tested whether adding an experimental drug called custirsen to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. It included 664 adults whose cancer had spread and who had already tried one prior treatment. The main go…

This study tested a personalized approach to radiation therapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. During standard chemoradiation, doctors used PET scans to see which parts of the tumor were still active and gave those areas a h…

This study tested a drug called AZD9291 in 171 adults from Asia Pacific with advanced non-small cell lung cancer that had stopped responding to earlier treatments. All patients had a specific gene mutation (T790M) in their tumors. The goal was to see if the drug could shrink tumo…

This study looked at whether switching from the immunotherapy durvalumab to the targeted drug sotorasib can better control locally advanced non-small cell lung cancer in patients with a KRAS G12C mutation and signs of remaining cancer (minimal residual disease). Ten participants …

This study tested an experimental drug called PF-06801591, which helps the immune system fight cancer. It involved 155 adults with advanced solid tumors or non-small-cell lung cancer. The goal was to find the right dose and check safety and effectiveness. This is not a cure, but …

This study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The goal was to see which combination worked best at shrinking tumors and slowing cancer growth. Participants received either one drug alon…

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This study looked at how safe and effective the drug Tabrecta is for people with a certain type of advanced lung cancer (MET exon 14 skipping mutation). 109 patients were followed for up to one year. The goal was to track side effects and see how well the drug controlled the canc…

This study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study tested the drug durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Participants received infusions every two weeks for up to 12 …

This phase 2 trial tested the drug DS-1062a in 137 adults with advanced or metastatic non-small cell lung cancer that has specific genetic changes and has worsened after targeted therapy and chemotherapy. The main goal was to see how many patients' tumors shrank or disappeared. T…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This completed study tracked 1290 lung cancer patients taking Lorbrena to see how often nervous system and liver side effects occur. Researchers aimed to identify factors that might increase these risks. The study does not test how well the drug works, only its safety in real-wor…

This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) after standard chemoradiation could better control stage III lung cancer compared to nivolumab alone. 105 patients were randomly assigned to one of the two treatment groups. The main goal was to s…

This study tested a combination of two drugs—pembrolizumab (Keytruda) and Imprime PGG—in 35 adults with advanced non-small cell lung cancer that had worsened after initial treatment. The goal was to find a safe dose and see if the combo could slow cancer growth. The trial was ear…

This completed Phase 4 trial tested two chemotherapy doses (standard and low) combined with the immunotherapy drug sintilimab in 20 adults with advanced squamous non-small cell lung cancer. The goal was to see how well the treatment shrank tumors and controlled the disease, while…

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This completed phase 2 trial tested whether adding a second immunotherapy drug (relatlimab) to the standard nivolumab-plus-chemotherapy regimen could shrink tumors more effectively in people with advanced or recurrent non-small cell lung cancer. The study enrolled 468 participant…

This early-phase trial tested an experimental oral drug called TPST-1495, given alone or with the immunotherapy Keytruda, in 89 people with advanced solid tumors (like colorectal, lung, and head/neck cancers) that had stopped responding to standard treatments. The main goals were…

This study tested whether using a non-invasive ventilation machine for at least 7 days before lung cancer surgery could reduce lung and heart complications. The trial included 300 patients with lung cancer who also had breathing problems, obesity, or heart failure. The goal was t…

This study tested a new drug combination (gimistotug plus other agents) in 35 adults with advanced non-small cell lung cancer who had already tried standard treatments. The main goal was to see if the combination could shrink tumors. Researchers also monitored side effects to und…

This study tested a new drug called ensartinib in 131 people with advanced solid tumors, including a type of lung cancer called ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors. The study was completed and helpe…

This study tested a combination of two drugs, RMC-4630 and sotorasib, in 47 adults with a specific type of advanced lung cancer (KRASG12C mutation) that had worsened after other treatments. The goal was to see if the combo could shrink tumors. The study is complete, and results w…

This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This study tested giving the immunotherapy drug tislelizumab, alone or with other drugs, before surgery for people with stage II to IIIA non-small cell lung cancer that could be removed. The goal was to see if this approach could shrink tumors and improve outcomes. 121 adults too…

This early-stage study tested a new treatment for people with advanced non-small cell lung cancer that had grown or returned after standard therapy. Researchers took patients' own immune cells, genetically modified them in a lab to target a protein called MAGE A10 on cancer cells…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This study tested a drug called trastuzumab deruxtecan in 152 people with a specific type of advanced lung cancer (HER2-mutated) that had gotten worse after standard treatment. The main goal was to see if the drug could shrink tumors. The approach uses a targeted therapy that del…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This study looked at whether giving a combination of immunotherapy and chemotherapy at a specific time of day helps people with advanced non-small cell lung cancer live longer without their disease getting worse. 210 adults who had not received prior treatment took part. The goal…

This study tested a combination of two drugs, atezolizumab and bevacizumab, as the first treatment for people with advanced non-squamous lung cancer that has a high number of genetic mutations. The goal was to see if this drug pair could slow down cancer growth. The trial enrolle…

This early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiation is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembrolizum…

This early-phase study tested the safety and effectiveness of a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to other treatments. The goal was to find the best dose and see if the drug could shrink …

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This study tested a new drug (ningetinib) combined with an existing targeted therapy (gefitinib) in 108 people with advanced lung cancer whose cancer had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors…

This phase 3 study tested adding the immunotherapy drug cemiplimab to standard chemotherapy for people with advanced non-small cell lung cancer. The goal was to see if the combination helps patients live longer and keeps the cancer from growing. About 789 participants received ei…

This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer. The drug targets both PD-1 and VEGF to attack cancer cells and cut off their blood supply. The study aimed to see if the drug shrinks tumors and how safe it is. Participants had stag…

This study tested whether a combination of two targeted drugs (savolitinib and osimertinib) works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to first-line …

This study tested a daily pill called sotorasib in 42 people with advanced lung cancer that has a specific KRAS G12C mutation and who had not received prior treatment. The goal was to see if the drug could shrink tumors and control the disease. Researchers also monitored side eff…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This study tested whether adding erlotinib to docetaxel chemotherapy helps people with advanced non-small cell lung cancer live longer without their disease getting worse. 156 adults whose cancer returned after initial treatment took part. Results focused on progression-free surv…

This study tested a new drug combination (tiragolumab plus atezolizumab) against a placebo plus atezolizumab in 135 people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combo could shrink tumors or delay cancer growth. P…

This early-phase study tested whether adding the drug copanlisib to the standard immune therapy durvalumab is safe and can help overcome resistance in people with stage III non-small cell lung cancer that cannot be removed by surgery. Eleven participants who had already received …

This study tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy before surgery helps people with early-stage non-small cell lung cancer. About 500 participants received either immunotherapy plus chemo, immunotherapy alone, or chemo alone b…

This study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims…

This study tested whether adding lenvatinib to the immunotherapy drug pembrolizumab helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. The trial included 623 adults whose tumors show at least 1% PD-L1. The goal was to see if the combin…

This study tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). The goal was to see if the combination could help control the cancer longer than standard …

This early-stage study tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goals were to find a safe do…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This study tested a new drug called lazertinib against an older drug, gefitinib, in 393 people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants took one of the two pills daily as their first treatment. The main goal was to see how long the c…

This study tested whether adding a new drug called tiragolumab to the standard immunotherapy atezolizumab works better than atezolizumab alone for people with advanced non-small cell lung cancer that has not been treated before. About 620 participants with high levels of a protei…

This study looked at whether giving palliative radiation to several tumor sites before starting standard immunotherapy and chemotherapy can help people with metastatic non-small cell lung cancer. Fifty adults with cancer that had spread and low PD-L1 levels received radiation to …

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This early-phase study tested the drug RAD001 (everolimus) together with radiation therapy in 26 people with advanced non-small cell lung cancer that could not be removed by surgery. The goal was to find the safest dose and see how well the combination worked. Participants took R…

This study tested a drug called serplulimab combined with chemotherapy for people with stage II-IIIA non-small cell lung cancer that could be removed by surgery. The treatment was given before and after surgery to see if it could shrink tumors and improve outcomes. 30 participant…

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…

This study tested a combination of two targeted drugs, encorafenib and binimetinib, in 98 people with advanced non-small cell lung cancer that has a specific BRAF gene mutation. The goal was to see if the drugs could shrink tumors and how safe they were. Participants had either n…

This study tested a combination of two drugs, nivolumab and ALT-803, in 67 people with advanced non-small cell lung cancer that had already been treated. The goal was to see if the combination is safe and how well it shrinks tumors. The approach aims to boost the immune system to…

This study tested whether giving drugs based on the genetic makeup of a person's lung cancer could help control the disease. About 50 adults with advanced non-small cell lung cancer received either immunotherapy (atezolizumab) alone or with chemotherapy, or targeted drugs like ve…

This study tested whether adding the drug camrelizumab to standard chemotherapy and radiation helps control lung cancer that has spread to the brain. It involved 60 adults with a type of lung cancer called non-small cell lung cancer who had not received chemotherapy before. The g…

This study tested a new way of giving radiation therapy combined with immunotherapy for people with advanced non-small cell lung cancer that does not have certain genetic mutations. The goal was to see if mixing high-dose and low-dose radiation could help the immune system fight …

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested a new pill called AZD3759 against standard targeted therapies (gefitinib or erlotinib) as a first treatment for people with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has spread to the brain. The trial involved 492 adults. T…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This study tested two oral medications, alectinib and crizotinib, in 303 people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) who had not received prior treatment. Participants took one of the drugs twice daily until their disease worsened…

This early-stage study tested whether adding PB101 (a patient's own natural killer cells) to standard targeted therapy is safe for people with advanced EGFR-mutated non-small cell lung cancer. Eight adults with stage IIIB/IV disease received the combination. The main goal was to …

This study looked at whether adding a special scope test (EBUS-TBNA) after a standard PET/CT scan can more accurately stage early-stage non-small cell lung cancer. About 150 patients who were being considered for precise radiation therapy (SBRT) took part. The goal was to see if …

This study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults gave a blood sample, and the results were compared to standard tissue tests. The goal was to see if the blood test is a reliable and practical option for guiding treatme…

This study tested a new method for PET scans that tracks breathing to get clearer images of lung tumors. 103 adults with small lung nodules took part. The goal was to see if this technique helps doctors find and measure lung cancer more accurately.

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week course, while the other had a shorter 4-week course guided by PET scans. The main goal was to see how patients felt during and after …

This study tested a low-cost, portable exercise program for people with non-small cell lung cancer after surgery. The goal was to help them manage severe fatigue and improve their quality of life. 235 adults took part, and the program was designed to be safe and practical for nea…

This study tested the safety of a special radiation schedule called Quad Shot for people with stage IV non-small cell lung cancer who are also receiving chemotherapy or immunotherapy. The Quad Shot delivers radiation in just 2 days per cycle, up to 3 cycles, to make it easier to …

This study tested whether a family-supported palliative care program could improve quality of life and emotional well-being in 110 people with advanced lung cancer. Participants were randomly assigned to either the family-supported program or standard nursing care for 8 weeks. Th…

This study looked at whether people with non-small cell lung cancer prefer getting their medication as a shot under the skin (subcutaneous) or through an IV drip. About 179 adults took part, including those with early-stage cancer after surgery and those with advanced cancer. The…

This study tested an investigational drug called ponsegromab in 187 adults with lung, pancreatic, or colorectal cancer who also had cachexia—a condition causing severe weight loss, loss of appetite, and fatigue. The goal was to see if ponsegromab could help patients gain weight a…

This study tested whether an education and support program can help family caregivers of cancer patients feel more confident and less anxious. About 484 caregivers and patients took part. Researchers compared different types of support to see which worked best.

This study tested whether a personalized exercise program helps people with early-stage lung cancer or cancer that spread to the lungs recover better after surgery. 182 participants were randomly assigned to either the exercise program or usual care. The main goal was to see if t…

This study tested whether a nutritional supplement with essential amino acids could help lung cancer patients who are losing weight build more protein in their bodies. 41 patients with advanced non-small cell lung cancer took part. The goal was to see if this supplement could red…

This study tested a new bendable surgical tool (SurgeoFlex Grasp) against a standard rigid tool in 100 adults with early-stage lung cancer undergoing keyhole surgery. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument clashes, and eases s…

This study examined Met receptor fragments in tissue and blood samples from 56 people with non-small cell lung cancer. Researchers used special lab tests to see which fragments are present and whether they are active. The goal was to learn more about the disease, not to test a ne…

This study looked at whether a simple blood test (liquid biopsy) can detect a specific resistance mutation called T790M in patients with advanced non-small cell lung cancer whose tumors stopped responding to initial targeted therapy. Researchers followed 70 patients in Tunisia, c…

This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked…

This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) that had stopped responding to targeted drugs. The goal was to find genetic changes in the cancer that cause resistance. By understanding these changes, doctors hope to match pati…

This study looked at 40 people with advanced non-small cell lung cancer who were starting treatment with the drug pembrolizumab. Researchers used special PET scans after each of the first three doses to see how the cancer's metabolism changed. The goal was to find out if early sc…

This study looked at how a new cancer drug called MK-1084 changes the way the body processes two other medicines, midazolam and digoxin. Twenty-eight healthy adults took part to help researchers understand if MK-1084 affects drug levels. The goal is to ensure safe dosing when MK-…

This study looked at whether adding a simple blood test (liquid biopsy) to the standard tissue biopsy helps find more genetic changes (EGFR mutations) in people with advanced non-small cell lung cancer. Over 500 patients who had not yet been treated took part. The goal was to see…

This study looked back at the medical records of 833 people with advanced non-small cell lung cancer to understand how they were treated and how long they lived. Researchers collected information from doctors' surveys across multiple countries. The goal was to learn about real-wo…

This study looked back at medical records of 60 people with advanced non-small cell lung cancer who received standard immunotherapy. Researchers checked whether those who also took beta-blockers (common heart medications) had different outcomes, like tumor shrinkage or survival. …

This study tested whether a combination of 6 markers from tumor tissue could predict how well patients with advanced non-small cell lung cancer respond to first-line treatment with pembrolizumab (immunotherapy) plus chemotherapy. Researchers analyzed tissue samples from 106 patie…

This completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…

This completed study looked at nearly 5,000 people with non-small cell lung cancer to see if information from electronic health records could produce the same results as a famous clinical trial called FLAURA. The goal was to understand when and how real-world data can be trusted …

This study looked at whether a special type of PET scan, called parametric imaging, can better predict if lung cancer will come back within a year after treatment. Forty patients with non-small cell lung cancer who were getting radiation and chemotherapy had two of these scans. T…

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 adults with advanced or metastatic cancer. The goal was to find safe doses for each drug combination to use in future, larger studies. The…

This study looked at whether a special type of scan called 4D PET-CT can help doctors plan radiation therapy better for people with non-small cell lung cancer. Seven patients had both a standard CT scan and a 4D PET-CT scan, and researchers compared the radiation target areas fro…

This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of…

This study followed 196 people with advanced lung or stomach cancer who had not yet received treatment. Researchers wanted to see if emotional distress before starting immunotherapy, along with certain blood markers of inflammation and metabolism, could predict how long patients …

This study looked at 62 people with ALK-positive lung cancer whose tumors had stopped responding to newer targeted drugs. Instead of a tissue biopsy, researchers used a blood test (liquid biopsy) to find genetic changes that cause resistance. The goal was to better understand the…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study looked at 212 adults with advanced non-small cell lung cancer who received the drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug works in every…

This study aimed to find immune-related biomarkers that could predict how well patients with non-small cell lung cancer respond to the drug atezolizumab. Researchers analyzed blood and tumor samples from 100 participants to track immune cell changes and genetic markers. The goal …

This study reviewed medical records of 350 Australian patients with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). Researchers looked at how long patients stayed on the drug osimertinib when it was given as their first or second treatment, and h…

This study created a detailed database of 518 adults with non-small cell lung cancer who had a genetic mutation. Researchers collected information on patients' age, smoking history, and cancer stage to see how these factors relate to different mutations. The goal was to better un…

This study looked at how the lung cancer drug AZD9291 (osimertinib) affects the breakdown of simvastatin, a common cholesterol medicine, in 52 adults with a specific type of advanced lung cancer (EGFR mutation-positive NSCLC) that had stopped responding to earlier treatments. The…